At the European Cancer Conference in Vienna at the end of September 2015 - Two late breaking abstracts have been selected for presentation at the prestigious Presidential Session on Sunday, September 27, 2015. (Click here to download session PDF)
LATE-BREAKING ABSTRACT: Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study
Speaker: J. Yao (USA)
LATE-BREAKING ABSTRACT: 177-Lu-Dotatate significantly improves progression-free survival in patients with mid gut neuroendocrine tumours: Results of the phase III NETTER-1 trial
Speaker: P. Ruszniewski (France)
NorCal CarciNET will be in Vienna and will post updates on these important developments as well as other topics of interest for those living with NETS.
